Originally developed by Actelion, from 2007 almorexant was being reported as a potential [[blockbuster drug]], as its novel mechanism of action (orexin receptor antagonism) was thought to produce better quality sleep and fewer side effects than the traditional [[benzodiazepine]]s and [[Z-drug]]s which dominated the multibillion-dollar insomnia medication market.<ref>[http://findarticles.com/p/articles/mi_hb5255/is_18/ai_n29394606/ Sleeping Beautifully] - CBS Business Network 24 Sep 2007</ref>
